Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission

Haematologica

Volumn 96, Issue 8, 2011, Pages 1106-1112

  Buyse, Marc ^a,b   Michiels, Stefan ^c   Squifflet, Pierre ^a   Lucchesi, Kathryn J ^d   Hellstrand, Kristoffer ^e   Brune, Mats L ^e   Castaigne, Sylvie ^f   Rowe, Jacob M ^g  

^a INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

^c JULES BORDET INSTITUTE   (Belgium)

^d MedVal Scientific Information Services   (United States)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f CENTRE HOSPITALIER DE VERSAILLES   (France)

^g RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Clinical trial interpretation; Immunotherapy; Leukemia free survival; Overall survival; Statistical analyses

Indexed keywords

HISTAMINE; RECOMBINANT INTERLEUKIN 2;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; HUMAN; KAPLAN MEIER METHOD; LEUKEMIA FREE SURVIVAL; LEUKEMIA REMISSION; LOW DRUG DOSE; MAINTENANCE THERAPY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); VALIDATION PROCESS;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; DISEASE-FREE SURVIVAL; HISTAMINE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MAINTENANCE CHEMOTHERAPY; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 79961097283     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.039131     Document Type: Article

References (39)

1. Piedbois P, Miller CJ. Surrogate endpoints for overall survival in advanced colorectal cancer: a clinician's perspective. Stat Methods Med Res. 2008;17(5):519-27.
2. Gill S, Sargent D. End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival? Oncologist. 2006;11(6):624-9.
3. Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007;25(33):5218-24.
4. Buyse M, Burzykowski T, Michiels S, Carroll K. Individual- and trial-level surrogacy in colorectal cancer. Stat Methods Med Res. 2008;17(5):467-75.
5. Burzykowski T, Buyse M, Yothers G, Sakamoto J, Sargent D. Exploring and validating surrogate endpoints in colorectal cancer. Lifetime Data Anal. 2008;14(1):54-64.
6. Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: literature- based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol. 2007;25(29):4562-8.
7. Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Lück HJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008;26(12):1987-92.
8. Piccart-Gebhart MJ, Burzykowski T, Buyse M, Sledge G, Carmichael J, Lück HJ, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 2008;26(12):1980-6.
9. Miksad RA, Zietemann V, Gothe R, Schwarzer R, Conrads-Frank A, Schnell- Inderst P, et al. Progression-free survival as a surrogate endpoint in advanced breast cancer. Int J Technol Assess Health Care. 2008;24(4):371-83.
10. Ramiah V, George DJ, Armstrong AJ. Clinical endpoints for drug development in prostate cancer. Curr Opin Urol. 2008;18 (3):303-8.
11. Bast RC, Thigpen JT, Arbuck SG, Basen- Engquist K, Burke LB, Freedman R, et al. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop. Gynecol Oncol. 2007;107(2): 173-6.
12. Ballman KV, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR, Jaeckle KA. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol. 2007;9(1):29-38.
13. Buyse ME, Squifflet P, Laporte S, et al. Prediction of survival benefits from progression- free survival in patients with advanced non small cell lung cancer: evidence from a pooled analysis of 2,838 patients randomized in 7 trials. J Clin Oncol 2008;26(15 suppl):428s.
14. Hotta K, Fujiwara Y, Matsuo K, Kiura K, Takigawa N, Tabata M, et al. Time to progression as a surrogate marker for overall survival in patients with advanced nonsmall cell lung cancer. J Thorac Oncol. 2009;4(3):311-7.
15. Michiels S, Le Maître A, Buyse M, Burzykowski T, Maillard E, Bogaerts J, et al. Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. Lancet Oncol. 2009;10(4):341-50.
16. Burzykowski T, Bank Y. Disease-free survival as a surrogate endpoint for overall survival in an adjuvant trial of curatively resected stomach cancer using individual patient data meta-analysis. J Clin Oncol. 2009;27(15 suppl):206s.
17. Milella M, Bria E, Carlini P, et al. Surrogate endpoints for overall survival (OS) in advanced pancreatic cancer (APC): analysis of randomized clinical trials (RCTS) exploring gemcitabine (G)-based combinations. J Clin Oncol 2007;25(18 suppl):216s.
18. Yothers G. Toward progression-free survival as a primary end point in advanced colorectal cancer. J Clin Oncol. 2007;25(33): 5153-4.
19. Levin VA, Ictech S, Hess KR. Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas. BMC Cancer. 2007;7:106.
20. Rowe JM, Xiaochun L, Cassileth PA, et al. Very poor survival of patients with AML who relapse after achieving a first complete remission: The Eastern Cooperative Oncology Group experience. Blood. 2005; 106(11):162a-3a.
21. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341(14):1051-62.
22. Breems DA, van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005;23(9):1969-78.
23. Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics. 2000;1 (1):49-67.
24. Buyse ME, Squifflet P, Allard SE, Bhagwat D, Rowe JM. Leukemia-free survival (LFS) as a surrogate for overall survival (OS) in AML patients in remission: a trial of a novel immunotherapy with histamine dihydrochloride plus low-dose IL-2 (HDC/IL-2). Haematologica. 2008;93(suppl 1):209-10.
25. Brune M, Castaigne S, Catalano J, Gehlsen K, Ho AD, Hofmann WK, et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood. 2006;108(1):88-96.
26. Wallhult EA, Whisnant JK, Nilsson BI, Bhagwat D, Hellstrand K, Brune ML. Quality of life during remission maintenance immunotherapy in acute myeloid leukemia: a prospective assessment using EORTC QLQ-C30 in a randomized phase III trial of histamine dihydrochloride plus low-dose interleukin-2. Haematologica. 2008;93(suppl 1):316.
27. Burchill SA. What do, can and should we learn from models to evaluate potential anticancer agents? Future Oncol. 2006;2(2): 201-11.
28. Hughes MD. Practical issues arising in an exploratory analysis evaluating progression- free survival as a surrogate endpoint for overall survival in advanced colorectal cancer. Stat Methods Med Res. 2008;17 (5):487-95.
29. Grothey A. Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective. Stat Methods Med Res. 2008;17(5):529-35.
30. Chakravarty A, Sridhara R. Use of progression- free survival as a surrogate marker in oncology trials: some regulatory issues. Stat Methods Med Res. 2008;17(5):515-8.
31. Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005;23(34):8664-70.
32. Burzykowski T, Molenberghs G, Buyse M, Geys H, Renard D. Validation of surrogate endpoints in multiple randomized clinical trials with failure-time endpoints. J R Stat Soc C. (Appl Stat) 2001;50:405-22.
33. Buyse M, Vangeneugden T, Bijnens L. Validation of biomarkers as surrogates forclinical endpoints. In: Bloom JC, Dean RA, eds. Biomarkers in Clinical Drug Develop - ment. New York: Marcel Dekker. 2003:149-68.
34. Collette L, Burzykowski T, Carroll KJ, Newling D, Morris T, Schroder FH. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. J Clin Oncol. 2005;23(25):6139-48.
35. Van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progressionfree survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Re - search and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24(18):2715-22.
36. Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008;26(35):5748-54.
37. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for meta - static breast cancer. J Clin Oncol. 2008; 26(34):5544-52.
38. Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 2008;112(12):4445-51.
39. National Cancer Institute. SEER Survival Data 1988-2005 (SEER 9). Available at: http://seer.cancer.gov/faststats/selections.p hp?series=cancer. Accessed February 3, 2010.